Zydus Lifesciences Limited

Zydus Lifesciences Limited

Aktie · INE010B01027 (XNSE)
Übersicht
AI-gestützte Analyse
Fundamental-Analyse
Was die Zahlen wirklich bedeuten – bevor der Markt es weiß.
Jetzt analysieren
News Sentiment
Kaufchance oder Alarmsignal? Was die aktuellen Nachrichten wirklich bedeuten.
Jetzt analysieren
Kaufen / Halten / Verkaufen
Kaufen, Halten oder Verkaufen? Das AI-Urteil auf einen Blick.
Jetzt analysieren
Risiko-Bewertung
Risiken erkennen, bevor sie zum Problem werden.
Jetzt analysieren
Fair Value
Zu teuer, fair bewertet oder ein Schnäppchen?
Jetzt analysieren
Neuste KI Analysen zu Zydus Lifesciences Limited
Kein Kurs
Schlusskurs XNSE 29.04.2026: 917,65 INR
29.04.2026 07:06
Aktuelle Kurse von Zydus Lifesciences Limited
BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNSE: NSE
NSE
ZYDUSLIFE.NS
INR
29.04.2026 07:06
917,65 INR
6,40 INR
+0,70 %
XBOM: MSE
MSE
ZYDUSLIFE.BO
INR
29.04.2026 06:48
916,80 INR
5,55 INR
+0,61 %
Free Float & Liquidität
Free Float 24,79 %
Shares Float 249,47 M
Ausstehende Aktien 1,01 B
Firmenprofil zu Zydus Lifesciences Limited Aktie
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company provides products in the therapeutic areas of pain management, neurology, liver diseases, and other areas. It also offers consumer wellness products, such as SugarFree and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

Unternehmensdaten

Name Zydus Lifesciences Limited
Firma Zydus Lifesciences Limited
Website https://www.zyduslife.com/zyduslife
Heimatbörse XNSE NSE
ISIN INE010B01027
Wertpapierart Aktie
Sektor Healthcare
Branche Drug Manufacturers - Specialty & Generic
Marktkapitalisierung 917 Mrd.
Land Indien
Währung INR
Mitarbeiter 24,4 T
Adresse Zydue Tower, Satellite Cross Road, 382481 Ahmedabad
IPO Datum 1995-05-15
Dividenden von 'Zydus Lifesciences Limited'
Ex-Datum Dividende pro Aktie
25.07.2025 11,00 INR
26.07.2024 3,00 INR
27.07.2023 6,00 INR
28.07.2022 2,50 INR
28.07.2021 3,50 INR
29.07.2021 3,50 INR
23.03.2020 3,50 INR
23.03.2020 3,50 INR
25.07.2019 3,50 INR
26.07.2019 3,50 INR

Aktien-Splits

Datum Split
06.10.2015 5:1
05.04.2010 3:2

Ticker Symbole

Name Symbol
MSE ZYDUSLIFE.BO
NSE CADILAHC.NS
NSE ZYDUSLIFE.NS
Weitere Aktien
Investoren, die Zydus Lifesciences Limited halten, haben auch folgende Aktien im Depot:
TRINIDAD TOB 20/30 REGS
TRINIDAD TOB 20/30 REGS Anleihe
Wuhan Keqian Biology Co.,Ltd
Wuhan Keqian Biology Co.,Ltd Aktie